The dramatic advances in the genetic, molecular, biologic, and pharmaceutical sciences in recent years have created challenges for regulatory agencies. The FDA, recognizing the need for concomitant advances in regulatory science, published the report Advancing Regulatory Science at FDA: Focus Areas of Regulatory Science (FARS) in early 2021.[82] The focus areas cross major FDA Strategic Initiatives, including Public Health Preparedness and Response, Increasing Choice and Competition through Innovation, Unleashing the Power of Data, and Empowering Patients and Consumers.[119]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.